News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Subscribe To Our Newsletter & Stay Updated
